Trials / Recruiting
RecruitingNCT06586515
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
A Phase 1a/1b Trial of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 630 (estimated)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to assess safety \& tolerability and antitumor activity of LY3962673 as monotherapy and in combination with other chemotherapy agents in participants with KRAS G12D-mutant advanced solid tumor types. The study is expected to last approximately 5 years.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY3962673 | Administered orally. |
| DRUG | Cetuximab | Administered intravenously. |
| DRUG | Gemcitabine | Administered intravenously. |
| DRUG | nab-paclitaxel | Administered intravenously. |
| DRUG | Oxaliplatin | Administered intravenously. |
| DRUG | leucovorin | Administered intravenously. |
| DRUG | Irinotecan | Administered intravenously. |
| DRUG | 5-fluorouracil | Administered intravenously. |
Timeline
- Start date
- 2024-09-12
- Primary completion
- 2029-03-01
- Completion
- 2029-03-01
- First posted
- 2024-09-19
- Last updated
- 2025-12-22
Locations
52 sites across 9 countries: United States, Canada, China, France, Germany, Ireland, Italy, Japan, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06586515. Inclusion in this directory is not an endorsement.